Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01875926 | ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers | PHASE1 | COMPLETED | 44 | — | — | May 1, 2013 | Oct 1, 2013 | Jul 13, 2018 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| ALX-0171 Oral Inhalation - Single Dose (SD) | EXPERIMENTAL | - |
| ALX-0171 Oral Inhalation - Multiple Dose (MD) | EXPERIMENTAL | - |
| ALX-0171 Intravenous (IV) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALX-0171 | BIOLOGICAL | single dose of 200 mg ALX-0171 via oral inhalation |
Inclusion Criteria: 1. Non-smoking healthy male volunteers, (18-55 years, extremes included). 2. Good health condition, as determined by medical history, physical examination and clinical laboratory testing 3. Body mass index (BMI) within normal range: 18.0 ≤ BMI \< 30.0 (kg/m2) 4. Haematology and ...